ProfileGDS5678 / 1443258_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 24% 26% 30% 24% 29% 29% 45% 33% 35% 29% 30% 31% 39% 30% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5889224
GSM967853U87-EV human glioblastoma xenograft - Control 22.5941326
GSM967854U87-EV human glioblastoma xenograft - Control 32.6863230
GSM967855U87-EV human glioblastoma xenograft - Control 42.5186824
GSM967856U87-EV human glioblastoma xenograft - Control 52.6069329
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7231129
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1203845
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.74433
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7779935
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6576929
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.669130
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6644631
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8895639
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6749330